Brentuximab vedotin (Bv) is becoming increasingly important in the treatment of Hodgkin lymphoma (HL), with improved outcomes and an overall favourable toxicity profile. However, Bv is associated with severe pulmonary toxicity when combined with bleomycin, suggesting that additive toxicity may be an important consideration. Furthermore, little has been published on tolerability in paediatric patients. We retrospectively evaluated the occurrence of pulmonary toxicity of Bv in 19 paediatric and young adult patients with relapsed or refractory HL. Patient characteristics, baseline health status, treatment regimens including cumulative doses of Bv, bleomycin, gemcitabine, radiation and carmustine, and the occurrence of pulmonary toxicity were collected. Seven (36Á8%) of the 19 patients were treated with Bv. The odds of pulmonary toxicity were 4Á0-fold higher (95% confidence interval 0Á55-29Á18) in patients exposed to Bv compared to unexposed patients in univariate analysis (P = 0Á17). Similar results were found in multivariable analysis. Pulmonary toxicity occurred frequently in our cohort and was more common in patients who received Bv than in patients who did not receive Bv, although this was not statistically significant. Because patients with HL are exposed to a myriad of therapies with potential for pulmonary toxicity, continuing to evaluate the risk associated with Bv is critical.
In paediatric patients with relapsed or refractory Hodgkin lymphoma (HL), intensification of conventional chemotherapy and radiation has shown limited success and high rates of treatment-associated morbidity, highlighting the need for alternative, targeted approaches in this high-risk population. Brentuximab vedotin (Bv) is an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E that has shown improved outcomes and overall reduced toxicity compared to standard salvage regimens (Younes et al, 2010 (Younes et al, , 2012 Moskowitz et al, 2015; Chen et al, 2016) . Bv is approved for use in relapsed or refractory HL, for high-risk patients in remission following autologous bone marrow transplant and, most recently, for upfront stage III or IV classical HL patients in combination with chemotherapy. Additional adult and paediatric clinical trials are currently underway to test the safety and efficacy of combining cytotoxic chemotherapy and targeted agents.
Pulmonary toxicity is an established adverse effect of several therapeutics used for HL such as bleomycin, gemcitabine, carmustine, and radiation. The incidence of acute pulmonary toxicity with Bv alone is low, between 0% and 5%, in the adult literature (Younes et al, 2010 (Younes et al, , 2013 Moskowitz et al, 2015) . Recently, a phase 3 trial involving de novo adult HL patients randomized patients to receive Bv with doxorubicin, vinblastine and dacarbazine (A+AVD), agents not classically associated with pulmonary toxicity, or to doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). Pulmonary toxicity was reported in 2% (12/662) of patients receiving A+AVD vs. 7% (44/649) in those receiving ABVD, with grade 3 or higher toxicity reported in 3% (21/ 659) vs. <1% (5/662), respectively (Connors et al, 2018) . Within paediatric HL, Bv monotherapy was well tolerated, had similar adverse events as adult monotherapy, and no evidence of pulmonary toxicity in the phase I/2 trial of Bv (Locatelli et al, 2017) .
In contrast, additive pulmonary toxicity has emerged with the concurrent administration of Bv with other pulmonary toxic agents. The Bv-associated pulmonary toxicity described is typically a non-infectious pneumonitis, interstitial lung research paper disease, or acute respiratory distress syndrome (ARDS) illness due to alveolar lung injury, and is manifested by nonspecific acute or subacute symptoms including dyspnea, cough, and fever. In a phase I combination trial of Bv with ABVD in adult relapsed/refractory patients, the incidence of grade 3 or higher acute pulmonary toxicity was 40% (11/25), including one death (Younes et al, 2013) . Comparatively, those receiving the same regimen without bleomycin (A+AVD) experienced no pulmonary toxicity (0/26). Given that the historic incidence of pulmonary toxicity with bleomycin monotherapy is estimated at 10-25%, this trial prompted a black box warning and contraindication of using Bv with bleomycin. Further, an adult study of SGN-30 (unconjugated Bv) with concurrent gemcitabine within in a regimen of gemcitabine, vinorelbine and dacarbazine (GVD) was stopped early due to grade 3-5 pneumonitis in 21% of patients (5/23), suggesting additive toxicity with the combination, though it should be noted that the SGN-30 was at a significantly higher dose level than used with Bv (Blum et al, 2010) . Unlike this study, a report from the ongoing phase 2 Children's Oncology Group (COG) trial (AHOD1221) evaluating Bv with gemcitabine in paediatric relapsed or refractory HL described no reported pulmonary toxicities in 42 patients treated (Cole et al, 2017) .
Brentuximab vedotin has been rapidly approved and incorporated into trials for adult and paediatric HL due to its targeted mechanism, high response rate and favourable toxicity profile. The severe pulmonary toxicity experienced in the phase I combination trial of Bv and bleomycin was unexpected and suggests that additive toxicity may be an important consideration for the use of Bv in combination regimens. In this retrospective cohort study, we aimed to describe the prevalence of pulmonary toxicity in paediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, specifically comparing the risk of toxicity in patients who received Bv as salvage therapy to those who did not receive Bv.
Methods
A retrospective cohort study was performed at Children's Hospital Colorado. All patients who were diagnosed with HL between 1 January 2006 and 31 December 2017 and were determined to have relapsed or refractory disease were considered for inclusion. There were no specific age requirements. Patients were excluded if there was insufficient data regarding therapy or less than 1 year of follow-up for the outcome. To identify our cohort, an existing programme registry database was used and manual review was performed to verify that each patient met inclusion and exclusion criteria. This study was approved by the University of Colorado Institutional Review Board.
To describe patient characteristics, exposures and outcomes, data was manually collected from the electronic health record (EHR). All data was collected from the EHR from time of diagnosis until 30 August 2017. Demographic information included age, sex, race and ethnicity. Baseline health characteristics included presence of prior pulmonary conditions (specifically asthma or chronic lung disease of prematurity), prior atopy (diagnosis of asthma, eczema and/ or allergic rhinitis) and smoke exposure. Clinical characteristics of disease and treatment were collected, including initial disease stage, presence of bulky mediastinal disease (defined as tumour greater than one-third of the thoracic diameter), presence of parenchymal lung involvement at diagnosis and any relapse, and the upfront and relapsed treatment regimens. Detailed information about specific treatment exposures was collected, including mean lung radiation dose, receipt of autologous stem cell transplant, and cumulative doses of bleomycin, gemcitabine and carmustine (BCNU). For each patient, data was collected on whether Bv was used and, if so, the cumulative dose was recorded, along with whether Bv was given as monotherapy or with other agents. Other pertinent information, such as the occurrence of pulmonary infection (defined by treatment for a radiographically-or microbiologically-proven infection, including viral, bacterial or fungal pathogens), respiratory failure (defined as need for positive pressure ventilation or intubation) and other lung-directed therapies received (including bronchodilators, montelukast, inhaled or systemic corticosteroids given for pulmonary concerns, and other anti-inflammatory therapies) was collected. Pulmonary function test (PFT) results were collected and reviewed by a single paediatric pulmonologist for confirmation of findings. Specifically, PFTs were categorized as having restrictive, obstructive, air trapping or diffusion abnormalities based upon forced expiratory volume (FEV; % predicted), forced vital capacity (FVC; % predicted), FEV/FVC (% predicted), total lung capacity (TLC; % predicted), residual volume (RV)/TLC and diffusing capacity of the lungs for carbon monoxide (DLCO: corrected for anaemia when able) measurements. The primary outcome, pulmonary toxicity, was defined as (i) Hypoxia ≥ grade 3 (Common Terminology Criteria for Adverse Events, v4.0 [CTCAE; https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_ 4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf] v4.0); or (ii) Dyspnea ≥ grade 3 (CTCAE v4.0); or (iii) DLCO < 50%, or a 50% decrease in DLCO (CTCAE v4.0) To reduce the risk of misclassification bias due to intrathoracic disease burden, the outcome was assessed during all treatment time points except for initial presentations at diagnosis or relapse. DLCO criteria was included given that Bv-associated toxicity is hypothesized to be largely mediated by alveolar injury, and was modelled from prior COG definitions for pulmonary toxicity in Hodgkin lymphoma trials (AHOD1331 [NCT0 2166463] and AHOD0031[NCT00025259]). Additionally, mortality was collected for descriptive purposes.
Statistical analysis was performed using R version 3.4.1 (https://www.r-project.org/). Demographic and clinical characteristics were summarized using medians and interquartile ranges for continuous variables, and counts and proportions for categorical variables. Associations between variables of interest and pulmonary toxicity were tested using Wilcoxon Rank Sum test for continuous variables and Chi-square tests or Fisher's exact tests for categorical variables. A logistic regression model was fit with pulmonary toxicity as the outcome and Bv as the exposure. A multivariable logistic regression model was fit with pulmonary toxicity as the outcome and Bv as the primary exposure, adjusting for cumulative bleomycin and lung radiation doses. The odds ratio (OR) and 95% confidence intervals (CIs) are presented.
Results
A total of 24 patients were evaluated at Children's Hospital Colorado for relapsed or refractory HL during the specified period; five patients were excluded due to inadequate data about therapy or outcomes, leaving a final cohort of 19. Fifteen patients were off therapy at the time of data collection (four of whom received Bv), three were on therapy (all of whom received Bv), and one was deceased (who had not received Bv). Seven patients were lost to follow-up, all of whom were off therapy at their last visit. The median followup time for all patients was 3Á8 years (interquartile range [IQR]: 2Á6, 5Á7) and was 1Á9 years (IQR: 1Á7, 2Á2) for the three patients on therapy and 4Á6 years (IQR: 3Á1, 5Á9) for those off therapy. Demographic data for the cohort is presented in Table I . The median age was 14Á5 years, 47% of patients were male and 95% of patients were Caucasian. Five (26%) patients had a pre-existing pulmonary condition and eight (42%) had pre-existing atopy. Three patients had a baseline exposure to smoke, 10 had no smoke exposure, and in six patients smoke exposure was unknown. Initial stage of disease was most commonly IIA (58%), half of the patients had bulky mediastinal disease at diagnosis, and parenchymal lung disease was present in 3 (16%) of patients at diagnosis and 4 (21%) of patients at any subsequent relapse. The majority of patients underwent autologous stem cell transplant (84%), all of whom received carmustine as a component of the carmustine, etoposide cytarabine, melphalan (BEAM) preparative regimen. Most patients (89%) received radiation impacting the lungs as part of salvage therapy. Among the cohort, seven patients received Bv, with six (86%) given as monotherapy and one (14%) concurrently with gemcitabine. In those treated with Bv, the median number of doses was five (range 3-15). All but one patient in the cohort (95%) had PFTs performed at least once, with a median of five PFT assessments performed per patient (range 0-15).
Overall, the patients exposed to Bv were similar in demographics and other treatment exposures to those not exposed to Bv (Table I ). There were no statistically significant differences between exposure groups for other baseline characteristics, including pre-existing pulmonary conditions or atopy, smoke exposure, initial disease stage, presence of bulky or parenchymal lung disease or other treatment exposures. There was also no difference between the Bv-exposed and unexposed groups in terms of abnormal PFT findings, respiratory failure and lung-directed therapies. A DLCO value of <80% occurred in 71% of Bv-exposed patients compared to 5% of Bv-unexposed patients (P = 0Á07). Additionally, of patients exposed to Bv, 57% (4/7) had at least one PFT classified as "restrictive", compared to 25% (3/12) of those unexposed (P = 0Á33). Only one patient experienced respiratory failure in the setting of Klebisella sepsis superimposed on radiation and carmustine-induced pneumonitis; this was also the sole patient death in the cohort.
The primary outcome, pulmonary toxicity, occurred in seven patients; of these patients, five developed hypoxia only, one developed dyspnoea only, and one developed both hypoxia and dyspnoea. No patients met the toxicity definition by DLCO criteria. Comparisons were performed between patients with (n = 7) and without (n = 12) pulmonary toxicity to assess for potential risk factors (Table II) . Of those exposed to Bv, 57% (4/7) developed pulmonary toxicity, compared to 25% (3/12) of those unexposed to Bv (P = 0Á33). There was no significant difference between those with and without pulmonary toxicity regarding exposure to or cumulative doses of bleomycin, carmustine, gemcitabine, lung radiation or occurrence of documented pulmonary infection (Table II) .
The primary exposure of interest, exposure to Bv, and the primary outcome, pulmonary toxicity, were tested for association via univariate logistic regression. The odds of pulmonary toxicity were 4Á0 (95% CI 0Á55-29Á18) times higher in patients exposed to Bv compared to patients unexposed to Bv (P = 0Á17). Similar results were found in multivariable analysis, adjusting for cumulative bleomycin and lung radiation doses (Table III) .
Discussion
In this single-institution retrospective cohort study, we sought to describe the occurrence of pulmonary toxicity experienced by paediatric and young adult patients with relapsed or refractory HL. Given the pulmonary toxicity reported in prior clinical trials with Bv, and the suggestion of additive effects with concurrent therapies (Blum et al, 2010; Younes et al, 2013) , we aimed to specifically compare the risk of toxicity between patients exposed versus unexposed to Bv and adjust for those concurrent therapies likely to confound this risk.
The overall prevalence of pulmonary toxicity in our cohort was high (37%); while this is probably indicative of a heavily pre-treated population, it is higher than reported in adults receiving salvage therapy and may indicate variability in risk by age. It is possible that the vulnerability of lung tissue to injury may change during the aging process; baseline immune function tends to be better in younger patients and a more robust immune response of younger patients could theoretically worsen the severity of treatment-induced lung injury (Castelo-Branco & Soveral, 2014) . Further, the higher prevalence of co-morbidities present in adults may minimize the reporting of symptoms, whereas younger patients who are otherwise healthy prior to their cancer diagnosis may more easily identify even subtle symptoms. Finally, there is a strong emphasis on comprehensive monitoring for late effects in paediatric oncology, including risk-based, exposurerelated clinical practice guidelines outlining pulmonary function testing needs in patients at risk for pulmonary toxicity, whereas PFT monitoring is much less defined in adult oncology (COG, 2013 , National Comprehensive Cancer Network [NCCN], 2018 . Thus, the increased focus on monitoring these patients may have contributed to the higher prevalence of toxicity found in this cohort.
Next, while a higher proportion of patients who were treated with Bv experienced pulmonary toxicity compared to patients who were not treated with Bv, this was not 6000 (4800, 6400) 6000 (4800, 6000) 6400 (5100, 6900) 0Á71
Bv, brentuximab vedotin; IQR, interquartile range. Table II . Univariate analysis of pulmonary toxicity by treatment exposures.
Exposure All (n = 19) No pulmonary toxicity (n = 12) Pulmonary toxicity (n = 7) P value
16 (84) 9 (75) 7 (100) 0Á26 Lung radiation, n (%)
17 (89) 10 (83) 7 (100) 0Á51 Pulmonary infection during therapy, n (%) 7 (37) 3 (25) 4 (57) 0Á33 statistically significant in our analysis. There were also no baseline or exposure differences between the groups which reached statistical significance. However, our analysis was limited by small sample size, which may have inhibited our ability to identify statistically significant differences. It should be noted that, while not statistically significant, the Bv-treated patients had higher slightly rates of pre-existing pulmonary conditions and atopy, more advanced disease at diagnosis (higher stage, bulky, and with parenchymal lung disease) and higher rates of exposure to carmustine, lung radiation and gemcitabine. These factors may have affected the susceptibility to developing pulmonary toxicity in these patients, regardless of receipt of Bv. Interestingly, the majority of patients in this cohort received Bv as monotherapy and pulmonary toxicity has not been reported in prior paediatric or adult Bv monotherapy experiences. However, toxicity assessment in those trials occurred primarily during a defined dose-limiting toxicity (DLT) period and development of pulmonary toxicity may take longer or require a higher cumulative Bv dose (Younes et al, 2010; Moskowitz et al, 2015; Perrot et al, 2016; Bartlett et al, 2017; Locatelli et al, 2017) . Furthermore, it is possible that cumulative exposure to various pulmonary toxic agents, even if not concurrent, could portend increased risk for pulmonary toxicity. Due to the small size of this cohort, we were not able to assess for changes in risk of pulmonary toxicity with each added exposure. Continued follow-up of patients who received Bv is needed to further delineate the incidence and mechanism of pulmonary toxicity. In addition to evaluating pulmonary toxicity as a single category, we also explored subtler differences in PFT results. Although more patients who were exposed to Bv had any occurrence of low DLCO (<80% predicted), the severity of these diffusion abnormalities did not meet our criteria for toxicity and our outcome was defined exclusively by the development of hypoxia and dyspnoea. In a recent pilot study of newly diagnosed, unfavourable risk adult HL patients receiving Bv with AVD followed by adjuvant involved site radiation therapy (ISRT), a mild reduction (mean reduction of 9% from baseline) in DLCO was described in most patients following four cycles of therapy (Kumar et al, 2016) . This reduction did not worsen with radiation, patients experienced only moderate symptoms (maximum of grade 2 dyspnoea and cough) and, on average, had returned to baseline function following ISRT. These findings suggest that DLCO may serve as a marker of Bv-associated lung injury; however, the functional relevance of this and its implication to the use of Bv with concurrent or sequential pulmonary-toxic therapies remains unclear.
Although retrospective analyses always pose a risk of incomplete data collection, a strength of this study was the availability of near complete therapy records for our patient cohort, allowing for the ability to calculate cumulative doses of relevant therapies to include in our analysis. As discussed, the study was limited by small sample size, which probably inhibited our ability to find statistical significance and control for all possible confounding variables in a full model. Furthermore, the creation of a comprehensive definition for pulmonary toxicity was challenging given a lack of well accepted criteria used in the literature, thus posing the risk of misclassification bias. We ultimately opted to focus on symptomatic progression (using dyspnoea, hypoxia) and development of significant diffusion abnormalities (using DLCO) based upon the prior Bv-associated toxicities described and recent COG definitions for dose modification of pulmonary toxic agents. Although DLCO is less effortdependent and more objective compared to other PFT parameters, it remained challenging to use due to an absence of well-defined thresholds with functional relevance and difficulty in addressing transient abnormalities. Our collaboration with a paediatric pulmonologist to provide expert interpretation of PFTs helped to alleviate this challenge. The ability to fully exclude disease burden as a component of pulmonary dysfunction was difficult, particularly in the setting of relapsed/refractory patients with often disseminated and bulky disease. We chose to not assess for pulmonary toxicity at initial presentation of relapse or progression to avoid confounding of our outcome by disease burden, and this was felt to be low risk for missing true toxicity given its timing prior to receipt of any salvage therapies.
While these limitations make it difficult to draw concrete conclusions from this study, the high prevalence of pulmonary toxicity in this population, particularly in patients who received Bv, warrants further investigation. The fact that Bv was predominantly used as monotherapy in this cohort suggests that additive pulmonary toxicity may occur over time and is not necessarily dependent on concurrent administration with other agents. Patients with HL are exposed to a variety of pulmonary toxic therapies, many of which have been shown to interact or be cumulative (Friedberg et al, 2003; Bredenfeld et al, 2004; Belknap et al, 2006; Castellino et al, 2011) . Further evaluation into the risk of Bv-associated pulmonary toxicity in this population using larger multicentre studies is necessary. Given its clinical efficacy, Bv has been incorporated into more upfront and relapsed treatment protocols and understanding potential pulmonary toxicity will be critical to better detect short-and long-term complications of therapy. 
